Loading...
XNAS
ACON
Market cap1mUSD
Jul 09, Last price  
2.91USD
1D
-1.36%
1Q
-9.91%
IPO
-100.00%
Name

Aclarion Inc

Chart & Performance

D1W1MN
XNAS:ACON chart
P/E
—
P/S
20.49
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-55.90%
Rev. gr., 5y
9.25%
Revenues
76k
+65.62%
26,89748,65260,29260,44475,40445,72475,730
Net income
-7m
L+3.44%
-4,019,258-4,635,245-4,950,290-7,068,593-4,911,374-6,992,927-7,233,629
CFO
-7m
L+35.90%
-4,171,233-1,793,803-2,349,949-4,949,112-3,646,947-5,271,609-7,164,204

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Aclarion, Inc., a healthcare technology enterprise based in San Mateo, California, was founded in 2008 and operates within the United States. The company specializes in creating software for magnetic resonance spectroscopy (MRS) applications. Its primary product is the NOCISCAN-LS Post-Processor suite, which features two key components: NOCICALC-LS, designed to analyze MRS data from discs to quantify degenerative pain biomarkers, and NOCIGRAM-LS, a software tool that assists in clinical decision-making. The company adopted its current name, Aclarion, Inc., in December 2021, having previously been known as Nocimed, Inc.
URL
http://aclarion.com/
IPO date
Apr 22, 2022
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT